Clinical Trials on Acute Myeloblastic Leukemia in Japan

Total 281 results

AstraZeneca

Completed

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Japan
GlaxoSmithKline

Completed

Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma

Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic

Japan
Osaka University
Japan Agency for Medical Research and Development

Recruiting

Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

Acute Myeloid Leukemia in Remission

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Genzyme, a Sanofi Company

Completed

A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)

Acute Myelogenous Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Japan
Astellas Pharma Inc

Completed

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)

Acute Myeloid Leukemia

Japan
Keio University

Completed

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Boehringer Ingelheim

Completed

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Japan
Gilead Sciences

Terminated

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)

Acute Myeloid Leukemia | Hematologic Malignancy

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
OncoVerity, Inc.
Janssen Pharmaceutical K.K.; argenx

Completed

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Leukemia, Myeloid, Acute

Japan
Japan Adult Leukemia Study Group

Unknown

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Lymphoblastic Leukemia, Acute

Japan
Japan Adult Leukemia Study Group

Unknown

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Lymphoblastic Leukemia, Acute

Japan
Japan Adult Leukemia Study Group

Completed

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Pfizer

Active, not recruiting

BESPONSA Injection 1 mg Special Investigation

Acute Lymphocytic Leukemia

Japan
Novartis Pharmaceuticals

Completed

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Leukemia, Myeloid, Acute

Japan
Amgen

Terminated

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States, Korea, Republic of, Australia, Japan, Germany, Canada
AbbVie

Completed

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Japan
GlaxoSmithKline

Completed

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphoblastic

Japan
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1)

Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Japan
GlaxoSmithKline

Completed

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Japan
GlaxoSmithKline

Completed

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular

Japan
Institut de Recherches Internationales Servier
Kyowa Kirin Co., Ltd.; ADIR, a Servier Group company

Completed

A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Japan
Pfizer

Completed

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Acute Myeloid Leukemia

Japan
Astellas Pharma Inc

Active, not recruiting

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Acute Myeloid Leukemia | FLT3-mutated Acute Myeloid Leukemia

Japan, Korea, Republic of, Taiwan
GlaxoSmithKline

Completed

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukaemia, Lymphocytic, Chronic

Korea, Republic of, Japan
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM)

B-cell Acute Lymphoblastic Leukemia

United States, United Kingdom, Japan, France
Genzyme, a Sanofi Company

Completed

A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukemia

Japan
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

Japan, United States
Princess Maxima Center for Pediatric Oncology
University of Milano Bicocca; Amgen Europe B.V

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21)

Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

Norway, Finland, Denmark, Netherlands, Hungary, Argentina, Australia, Austria, Belgium, Czechia, France, Germany, Ireland, Italy, Japan, Portugal, Saudi Arabia, Sweden
AbbVie

Recruiting

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Israel, Japan, Australia, Korea, Republic of
Sumitomo Pharma America, Inc.

Recruiting

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

Leukemia, Myeloid, Acute | Leukemia, Lymphocytic, Acute

Japan, United States
Novartis Pharmaceuticals

Recruiting

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

FLT3-mutated Acute Myeloid Leukemia

Korea, Republic of, Germany, Italy, Turkey, Czechia, Jordan, Slovenia, Austria, Poland, Japan, Russian Federation, United States, Greece
Novartis Pharmaceuticals

Completed

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Acute Myeloid Leukemia

Japan, Taiwan, Hong Kong, Thailand, Korea, Republic of, Russian Federation, Vietnam
Astellas Pharma Global Development, Inc.

Completed

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States, Japan
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia

Taiwan, United States, Brazil, Japan, Italy, Korea, Republic of, Canada, China, Israel, Romania
AstraZeneca

Completed

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients (SPARK-AML1)

Acute Myeloid Leukemia

United States, Italy, United Kingdom, Romania, Japan, Australia, Germany, Spain, France
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Leukemia, Acute Myeloid (AML)

Japan, United States, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Poland, Spain, Taiwan, Turkey, United Kingdom
AbbVie

Active, not recruiting

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia (AML)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Puerto Rico, Russian Federation, South Africa, Spain, T... and more
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

AML and High Risk MDS

Germany, Italy, France, Netherlands, United States, Australia, Japan

3

Subscribe